TMCnet News

Genocea Biosciences, Inc. Announces Closing of Initial Public Offering
[February 10, 2014]

Genocea Biosciences, Inc. Announces Closing of Initial Public Offering


CAMBRIDGE, Mass. --(Business Wire)--

Genocea Biosciences, Inc. today announced the closing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $12.00 per share. After underwriting discounts and commissions and estimated offering expenses, Genocea received net proceeds of approximately $61.4 million, excluding estimated offering expenses. The shares are listed on the NASDAQ Global Market under the ticker symbol "GNCA."

Citigroup and Cowen and Company are acting as joint book-running managers for the offering. Stifel is acting as lead manager and Needham & Company, LLC is acting as co-manager.

A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on February 4, 2014. This press release shall not onstitute an offer to sell or a solicitation of an offer to buy and there shall not be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.



A copy of the final prospectus related to these securities may be obtained from Citigroup c/o Broadridge Financial Solutions, 1155 Long Island Ave., Edgewood, NY 11717, by calling (800) 831-9146, or by emailing [email protected], or Cowen and Company c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by calling (631) 274-2806, or by fax (631) 254-7140.

About Genocea Biosciences, Inc.


Genocea is harnessing the power of T cell immunity to develop the next generation of vaccines. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of infectious disease pathogens, but are difficult to target using traditional vaccine discovery methods. Genocea is able to identify protective T cell antigens in humans exposed to a pathogen using ATLAS™, its proprietary technology platform, potentially enabling vaccines against pathogens for which vaccine solutions do not exist or are sub-optimal. Genocea's pipeline of novel T cell vaccines includes GEN-003 for HSV-2 therapy, GEN-004, and earlier-stage programs in chlamydia, HSV-2 prophylaxis and malaria.


[ Back To TMCnet.com's Homepage ]